180 related articles for article (PubMed ID: 18054750)
1. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis.
García Rodríguez LA; Ruigómez A; Panés J
Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1418-23. PubMed ID: 18054750
[TBL] [Abstract][Full Text] [Related]
2. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.
Canani RB; Cirillo P; Roggero P; Romano C; Malamisura B; Terrin G; Passariello A; Manguso F; Morelli L; Guarino A;
Pediatrics; 2006 May; 117(5):e817-20. PubMed ID: 16651285
[TBL] [Abstract][Full Text] [Related]
3. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
Park W; Hicks DM; Khandwala F; Richter JE; Abelson TI; Milstein C; Vaezi MF
Laryngoscope; 2005 Jul; 115(7):1230-8. PubMed ID: 15995512
[TBL] [Abstract][Full Text] [Related]
4. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk?
Garcia Rodríguez LA; Ruigómez A
Epidemiology; 1997 Sep; 8(5):571-4. PubMed ID: 9270961
[TBL] [Abstract][Full Text] [Related]
5. Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study.
Wei L; Ratnayake L; Phillips G; McGuigan CC; Morant SV; Flynn RW; Mackenzie IS; MacDonald TM
Br J Clin Pharmacol; 2017 Jun; 83(6):1298-1308. PubMed ID: 28054368
[TBL] [Abstract][Full Text] [Related]
6. Long-term proton pump inhibitor therapy and risk of hip fracture.
Yang YX; Lewis JD; Epstein S; Metz DC
JAMA; 2006 Dec; 296(24):2947-53. PubMed ID: 17190895
[TBL] [Abstract][Full Text] [Related]
7. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Harris RA; Kuppermann M; Richter JE
Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
[TBL] [Abstract][Full Text] [Related]
8. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy.
Lin KJ; Hernández-Díaz S; García Rodríguez LA
Gastroenterology; 2011 Jul; 141(1):71-9. PubMed ID: 21458456
[TBL] [Abstract][Full Text] [Related]
9. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability.
van Vlerken LG; Huisman EJ; van Hoek B; Renooij W; de Rooij FW; Siersema PD; van Erpecum KJ
Eur J Clin Invest; 2012 Jul; 42(7):760-7. PubMed ID: 22288900
[TBL] [Abstract][Full Text] [Related]
10. Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities.
Ruigómez A; García Rodríguez LA; Panés J
Clin Gastroenterol Hepatol; 2007 Apr; 5(4):465-9. PubMed ID: 17445753
[TBL] [Abstract][Full Text] [Related]
11. Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression.
Abdul-Hussein M; Freeman J; Castell D
Pharmacotherapy; 2015 Dec; 35(12):1124-9. PubMed ID: 26621819
[TBL] [Abstract][Full Text] [Related]
12. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
Hall J; Dodd S; Durkin M; Sloan S
Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
[TBL] [Abstract][Full Text] [Related]
13. Management of symptoms in step-down therapy of gastroesophageal reflux disease.
Mine S; Iida T; Tabata T; Kishikawa H; Tanaka Y
J Gastroenterol Hepatol; 2005 Sep; 20(9):1365-70. PubMed ID: 16105122
[TBL] [Abstract][Full Text] [Related]
14. Prenatal exposure to acid-suppressive drugs and the risk of childhood asthma: a population-based Danish cohort study.
Andersen AB; Erichsen R; Farkas DK; Mehnert F; Ehrenstein V; Sørensen HT
Aliment Pharmacol Ther; 2012 May; 35(10):1190-8. PubMed ID: 22443179
[TBL] [Abstract][Full Text] [Related]
15. Inappropriate use of proton pump inhibitors.
Molloy D; Molloy A; O'Loughlin C; Falconer M; Hennessy M
Ir J Med Sci; 2010 Mar; 179(1):73-5. PubMed ID: 19763673
[TBL] [Abstract][Full Text] [Related]
16. [PPI: new strategies for GERD].
Hoshino E; Ishiyama A; Tsuchida T
Nihon Rinsho; 2004 Aug; 62(8):1570-6. PubMed ID: 15344553
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration.
Hassall E; Kerr W; El-Serag HB
J Pediatr; 2007 Mar; 150(3):262-7, 267.e1. PubMed ID: 17307542
[TBL] [Abstract][Full Text] [Related]
18. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
[TBL] [Abstract][Full Text] [Related]
19. [Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist].
Habu Y; Oyasu K; Wakamatsu T; Sumitomo Y; Kiyota K; Inokuchi H; Kawai K
Nihon Rinsho; 2000 Sep; 58(9):1881-5. PubMed ID: 11004820
[TBL] [Abstract][Full Text] [Related]
20. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
Inadomi JM; McIntyre L; Bernard L; Fendrick AM
Am J Gastroenterol; 2003 Sep; 98(9):1940-4. PubMed ID: 14499769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
